In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.
Cemiplimab may yield more favorable outcomes in patients with non–small cell lung cancer (NSCLC) with high programmed cell death-ligand (PD-L1) expression and no genomic aberrations, compared with pembrolizumab, say findings from a meta-analysis published in Therapeutic Advances in Medical Oncology.
In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials (RCTs) of the 2 programmed cell death-1 (PD-1)/PD-L1 inhibitors in patients with advanced disease and PD-L1 of at least 50%. Alhough the treatments showed comparable overall survival (OS), cemiplimab was associated with statistically significant improvements in progression-free survival (PFS) and overall response rate (ORR) vs pembrolizumab.
“While each new treatment has provided significant benefits to patients, the clinical evidence base for trials targeting high PD-L1 expression is still evolving and uncertainty remains regarding the most appropriate first-line therapeutic strategies,” wrote the researchers. “Moreover, there are no trials that directly compare the efficacy and safety between these immunotherapies. Such an analysis might help clinicians to optimize immune-oncology monotherapy especially in patients with high PD-L1 expression.”
Data was pulled from 2 pembrolizumab trials—KEYNOTE-024 and KEYNOTE-042—and from the EMPOWER-Lung 1 trial of cemiplimab. The researchers analyzed data from the PD-L1 ≥50% populations, rather than the intent-to-treatment populations, from the EMPOWER-Lung 1 and KEYNOTE-042 trials for efficacy evaluation in order to align with the target population.
At 3 months (HR, 0.81; 95% CI, 0.54-1.19) and 30 months (HR, 0.70; 95% CI, 0.40-1.22), OS with cemiplimab was comparable to that with pembrolizumab, although the researchers noted that at 2 years, more patients receiving cemiplimab were alive, and significantly more were alive without disease progression, compared with patients receiving pembrolizumab. From month 6 (HR, 0.62; 95% CI, 0.15-0.83) through month 30 (HR, 0.32; 95% CI, 0.15-0.68), cemiplimab yielded statistically significant improvements in PFS vs pembrolizumab.
Odds of demonstrating an objective response were also favorable for cemiplimab compared with pembrolizumab (odds ratio, 1.64; 95% CI, 1.04-2.62). Safety between the 2 treatments was comparable, with no evidence of differences in grade 3-5 adverse events (AEs), immune-related AEs, or all-cause discontinuation due to AEs.
In addition to cemiplimab and pembrolizumab, atezolizumab has been approved for this group of patients based on data from the IMpower110 trial; however, this trial was excluded in the current analysis due to an incompatible PD-L1 assay used for patient selection. The MYSTIC trial of durvalumab was also excluded because the treatment is not indicated for monotherapy for advanced NSCLC due to failure to meet the study’s primary end point.
“The current systematic literature review focused only on immune-oncology [IO] monotherapies that were licensed or in the process of being evaluated by the FDA for patients with high PD-L1 expression. Nivolumab monotherapy was excluded since it was not indicated for the target population with high PD-L1 expression, given the unfavorable efficacy results from the CheckMate 026 trial,” the authors concluded. “Future analyses should consider the inclusion of IO combination regimens to assess whether the addition of chemotherapy is beneficial for patients with high PD-L1 expression, as there have been discrepancies in the results from several recently published RCTs and results from indirect comparisons suggest a potential benefit of IO combination regimens for particular subgroups.”
Reference
Freemantle N, Xu Y, Wilson F, et al. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ≥50%. Ther Adv Med Oncol. Published online June 16, 2022. doi:10.1177/17588359221105024
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More